Combination of clopidogrel and everolimus dramatically reduced the development of transplant arteriosclerosis in murine aortic allografts

Transplant International

Volumn 23, Issue 9, 2010, Pages 959-966

  Eckl, Sebastian ^a   Heim, Christian ^a   Abele Ohl, Silke ^a   Hoffmann, Julia ^a   Ramsperger Gleixner, Martina ^a   Weyand, Michael ^a   Ensminger, Stephan M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

clopidogrel; mammalian target of rapamycin inhibitor; platelets; transplant arteriosclerosis

Indexed keywords

CLOPIDOGREL; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA GRAFT; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; C57BL 6 MOUSE; CBA MOUSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; AORTA, ABDOMINAL; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIROLIMUS; TICLOPIDINE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955233103     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01072.x     Document Type: Article

References (48)

1. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report - 2008. J Heart Lung Transplant 2008 27 : 943.
2. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000 51 : 81.
3. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007 116 : 1274.
4. Shi C, Russell ME, Bianchi C, Newell JB, Haber E, et al. Murine model of accelerated transplant arteriosclerosis. Circ Res 1994 75 : 199.
5. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 : 591.
6. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004 61 : 498.
7. Abele S, Weyand M, Wollin M, et al. Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg 2006 131 : 1161.
8. Abele S, Spriewald BM, Ramsperger-Gleixner M, et al. Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. Transplantation 2009 87 : 207.
9. Fateh-Moghadam S, Bocksch W, Ruf A, et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation 2000 102 : 890.
10. Hognestad A, Michelsen A, Brosstad F, et al. Platelet activation in heart transplant recipients. Clin Transplant 2004 18 : 142.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 348 : 1329.
12. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494.
13. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001 409 : 202.
14. Santa-Cruz RA, Steinhubl SR. Clopidogrel: how good is it and how does it work? Curr Cardiol Rep 2004 6 : 264.
15. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000 84 : 891.
16. Koulack J, McAlister VC, Giacomantonio CA, Bitter-Suermann H, MacDonald AS, Lee TD. Development of a mouse aortic transplant model of chronic rejection. Microsurgery 1995 16 : 110.
17. Ensminger SM, Billing JS, Morris PJ, Wood KJ. Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Lung Transplant 2000 19 : 1039.
18. Ensminger SM, Spriewald BM, Witzke O, et al. Kinetics of transplant arteriosclerosis in MHC-Class I mismatched and fully allogeneic mouse aortic allografts. Transplantation 2002 73 : 1068.
19. Lietz K, Miller LW. Current understanding and management of allograft vasculopathy. Semin Thorac Cardiovasc Surg 2004 16 : 386.
20. Libby P, Pober JS. Chronic rejection. Immunity 2001 14 : 387.
21. Matsumoto Y, Hof A, Baumlin Y, Hof RP. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation 2003 76 : 1166.
22. Nikolova Z, Hof A, Baumlin Y, Hof RP. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. Transplantation 2001 72 : 168.
23. Nikolova Z, Hof A, Baumlin Y, Hof RP. Efficacy of SDZ RAD compared with CsA monotherapy and combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol 2001 9 : 43.
24. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007 26 : 250.
25. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847.
26. Valantine H, Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 2005 24 (Suppl. 4 S185 discussion S210-1.
27. Matsumoto Y, Hof A, Baumlin Y, Müller M, Hof RP. Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice. Transplantation 2004 78 : 345.
28. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997 64 : 36.
29. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998 30 : 2200.
30. Viklicky O, Zou H, Müller V, Lacha J, Szabó A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000 69 : 497.
31. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999 100 : 67.
32. Stepkowski SM, Napoli KL, Wang ME, Qu X, Chou TC, Kahan BD. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996 62 : 986.
33. Schmid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995 60 : 729.
34. Raichlin E, Kushwaha SS. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr Opin Organ Transplant 2008 13 : 543.
35. Khandoga A, Biberthaler P, Enders G, et al. Platelet adhesion mediated by fibrinogen-intercellular adhesion molecule-1 binding induces tissue injury in the postischemic liver in vivo. Transplantation 2002 74 : 681.
36. Yu G, Rux AH, Ma P, Bdeir K, Sachais BS. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood 2005 105 : 3545.
37. Stoica SC, Goddard M, Large SR. The endothelium in clinical cardiac transplantation. Ann Thorac Surg 2002 73 : 1002.
38. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984 226 : 544.
39. Liu J, Farmer JD Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991 66 : 807.
40. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001 20 : 2476.
41. Wasowska BA, Zheng XX, Strom TB, Kupieck-Weglinski JW. Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. Transplantation 2001 71 : 1179.
42. Khanna AK, Hosenpud JS, Plummer MS, Hosenpud JD, et al. Analysis of transforming growth factor-beta and profibrogenic molecules in a rat cardiac allograft model treated with cyclosporine. Transplantation 2002 73 : 1543.
43. Waiser J, Dell K, Böhler T, et al. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. Nephrol Dial Transplant 2002 17 : 1568.
44. Moien-Afshari F, McManus BM, Laher I. Immunosuppression and transplant vascular disease: benefits and adverse effects. Pharmacol Ther 2003 100 : 141.
45. Mennander A, Paavonen T, Hayry P. Cyclosporine-induced endothelialitis and accelerated arteriosclerosis in chronic allograft rejection. Transplant Proc 1992 24 : 341.
46. Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J 1998 17 : 3101.
47. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000 404 : 402.
48. Dietrich H, Hu Y, Zou Y, et al. Mouse model of transplant arteriosclerosis: role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 2000 20 : 343.